A recent phase 3 study showed that acoramidis (Attruby), an oral treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), cut the risk of cardiovascular death or repeat hospital stays by 49 percent compared with a placebo (an inactive treatment).

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Sign up with your email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a Member? Log in

The U.S. Food and Drug Administration (FDA) approved the drug in 2024, but the full study results were published in 2025. The findings give doctors and people living with ATTR-CM more information and insight into how the drug works, especially over time. The data also reinforces the importance of early diagnosis and treatment.

What Is Acoramidis?

Acoramidis is a transthyretin stabilizer used to treat ATTR-CM, a type of cardiac amyloidosis. In this condition, abnormal proteins called amyloids build up in the heart, making it stiff and less able to pump blood.

Acoramidis works by preventing transthyretin, a protein made in the liver, from breaking apart and forming harmful amyloid deposits. The medication is approved for both wild-type and hereditary forms of ATTR-CM and is taken as a tablet, usually twice daily.

What the Study Found

The phase 3 trial included more than 600 adults with ATTR-CM. Participants took either acoramidis or a placebo and were followed for 30 months. Key findings include the following:

• A 49 percent lower risk of cardiovascular death or repeat hospitalizations in the acoramidis group
• People treated with acoramidis had 53 fewer serious heart events for every 100 compared with placebo
• Benefits that began within the first month and increased over time
• Continued benefits at 42 months for people who remained on the drug

What About Side Effects?

The study didn’t report side effects. However, the drug’s prescribing label lists common side effects such as diarrhea and upper abdominal pain. Rare side effects may include a temporary rise in creatinine (a marker of kidney function) and a drop in estimated glomerular filtration rate (eGFR, a measure of how well the kidneys filter waste).

Why This Matters if You’re Living With ATTR-CM

Many people with transthyretin amyloid cardiomyopathy face delays in diagnosis and have limited treatment options. This study suggests that acoramidis may significantly reduce serious heart risks — and that starting treatment early could offer the most benefit over time. Still, the authors noted that more research is needed to see how well acoramidis works in different groups and in everyday life.

The findings also reinforce what doctors and researchers are learning: ATTR-CM is a condition in which quickly starting treatment matters, and early diagnosis can make a difference.

If you’ve been diagnosed with ATTR-CM — or think you may have symptoms — talk with your healthcare provider. You can explore whether acoramidis or another treatment is right for you and build a care plan that supports your long-term heart health.

Learn about the various treatments for amyloidosis and their side effects.

Join the Conversation

On MyAmyloidosisTeam, people share their experiences with amyloidosis, get advice, and find support from others who understand.

Are you being treated for ATTR-CM? How has your experience been? Let others know in the comments below.